On the occasion of the green light for the reimbursement of ofatumumab, the first highly effective home treatment indicated for adults with relapsing remitting multiple sclerosis, the president of the Italian Multiple Sclerosis Foundation explains the socio-economic impact of the disease and the importance of personalized therapy .